Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fezolinetant long-term safety in menopause
NCT04003389Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Jul 2019
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of fezolinetant in vasomotor symptoms, sponsored by Astellas Pharma. Started Jul 2019; status: completed.
02
Drugs
fezolinetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT04003389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04003389.